US FDA approves saxagliptin with CV study requirement
This article was originally published in Scrip
The US FDA has approved Bristol-Myers Squibb/AstraZeneca's DPP-4 inhibitor Onglyza (saxagliptin) for type 2 diabetes.
You may also be interested in...
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.
Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.